keyword
https://read.qxmd.com/read/38536067/targeted-and-shallow-whole-genome-sequencing-identifies-therapeutic-opportunities-in-p53abn-endometrial-cancers
#1
JOURNAL ARTICLE
Amy Jamieson, Juliana Sobral de Barros, Dawn R Cochrane, J Maxwell Douglas, Sameer Shankar, Branden J Lynch, Samuel Leung, Spencer Martin, Janine Senz, Amy Lum, Yvette Drew, C Blake Gilks, David G Huntsman, Jessica N McAlpine
PURPOSE: Shallow whole genome sequencing (sWGS) can detect copy number (CN) aberrations. In high-grade serous ovarian (HGSOC) sWGS identified CN signatures such as homologous recombination deficiency (HRD) to direct therapy. We applied sWGS with targeted sequencing to p53abn endometrial cancers (ECs) to identify additional prognostic stratification and therapeutic opportunities. EXPERIMENTAL DESIGN: sWGS and targeted panel sequencing was performed on formalin-fixed paraffin-embedded p53abn ECs...
March 27, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38444645/complicated-pancreatic-fistula-after-gynecologic-surgery-for-left-fallopian-tube-carcinosarcoma-a-case-report
#2
Kazuna Matsutani, Yasuto Kinose, Mayuko Kato, Michiko Kodama, Kenjiro Sawada, Tadashi Kimura
Pancreatic fistulas are rare after gynecologic surgeries but are sometimes difficult to manage. A 62-year-old woman was admitted to a local hospital with acute abdominal pain. Computed tomography (CT) images showed subileus and an obstruction site in the transverse/descending colon, with invasion of peritoneal metastasis. A metal stent was placed in the bowel through colonoscopy. Suspecting advanced-stage ovarian cancer, the patient was referred to a tertiary hospital. Diagnostic laparoscopy was performed prior to neoadjuvant chemotherapy...
March 2024: Case Reports in Women's Health
https://read.qxmd.com/read/38357982/trichorhinophalangeal-syndrome-type-1-immunohistochemical-expression-in-carcinomas-of-gynecologic-origin
#3
JOURNAL ARTICLE
Felipe Ruiz, Youley Tjendra, Nicolas Millan, Carmen Gomez-Fernandez, Andre Pinto
Trichorhinophalangeal syndrome type 1 (TRPS1) is a new reportedly sensitive and specific immunohistochemical marker for carcinomas of breast origin, including triple-negative (estrogen receptor, progesterone receptor, and HER2) tumors. In our practice, we have observed a subset of cases of nonmammary carcinomas that are positive for TRPS1, with higher frequency in cytology effusion samples with metastatic gynecologic malignancies. This study aimed to evaluate the expression of TRPS1 in a large tissue cohort of Müllerian carcinomas...
February 15, 2024: American Journal of Surgical Pathology
https://read.qxmd.com/read/38326227/conservative-management-of-burst-adbomen-after-interval-cytoreduction-surgery-of-ovarian-carcinosarcoma
#4
JOURNAL ARTICLE
Alberto Rafael Guijarro-Campillo, Victor Lago, Salvador Pous-Serrano, Santiago Domingo
No abstract text is available yet for this article.
February 7, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38273934/successful-treatment-of-stage-ivb-ovarian-carcinosarcoma-with-parp-inhibitor-a-case-report
#5
Jessica D St Laurent, Mary Kathryn Abel, Joyce Liu, Bradley J Quade, Michelle R Davis
•Ovarian carcinosarcoma is a rare ovarian cancer histology that has limited treatment options.•In this study, we present an unusual association between carcinosarcoma and a STIC lesion.•In select patients with carcinosarcoma, PARP inhibition may provide clinical benefit.
February 2024: Gynecologic Oncology Reports
https://read.qxmd.com/read/38256351/rate-of-vaginal-cuff-dehiscence-when-using-vicryl-poliglactyn-910-compared-to-pds-polydioxanone-for-vaginal-cuff-closure-in-laparoscopic-hysterectomy
#6
JOURNAL ARTICLE
Francesco Giuseppe Cannone, Livia Cormaci, Carla Ettore, Ferdinando Antonio Gulino, Giosuè Giordano Incognito, Domenico Benvenuto, Giuseppe Ettore
Objective: To compare the vaginal cuff dehiscence (VCD) rates using Vicryl (Poliglactyn 910) and Polydioxanone (PDS) in patients who underwent laparoscopic hysterectomy. Materials and methods: A retrospective, monocentric study was conducted, including all patients undergoing laparoscopic hysterectomy at the Department of Obstetrics and Gynaecology, Azienda di Rilievo Nazionale e di Alta Specializzazione (ARNAS) Garibaldi Nesima, Catania, between January 2014 and December 2021. Patients underwent hysterectomy for benign gynecologic pathologies (endometriosis, leiomyomas, or benign pelvic pathologies) or malignant gynecologic pathologies (endometrium cancer, complex endometrial hyperplasia, ovarian cancer, cervix cancer, or uterine carcinosarcoma)...
January 3, 2024: Medicina
https://read.qxmd.com/read/38234609/comprehensive-analysis-and-immunohistochemistry-localization-of-nrp1-expression-in-pancancer-and-normal-individual-tissues-in-relation-to-sars%C3%A2-cov%C3%A2-2-susceptibility
#7
JOURNAL ARTICLE
Jiewen Fu, Jiayue He, Lianmei Zhang, Jingliang Cheng, Pengfei Zhang, Chunli Wei, Junjiang Fu, Dabing Li
Neuropilin 1 (NRP1/CD304) is a typical membrane-bound co-receptor for vascular endothelial growth factor, semaphorin family members and viral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, NRP1 expression levels across cancer types and the potential role of SARS-CoV-2 infection in patients with cancer are not clear. Online databases, such as The Cancer Genome Atlas database of Human Protein Atlas, Gene Expression Profiling Interactive Analysis and cBioPortal were used for the expression analysis in this study...
February 2024: Experimental and Therapeutic Medicine
https://read.qxmd.com/read/38205105/ovarian-carcinosarcoma-rare-histology-which-never-fails-to-be-aggressive
#8
Dimpy Begum, Aparajita, Upasana Baruah, Debabrata Barmon
No abstract text is available yet for this article.
December 2023: Journal of Obstetrics and Gynaecology of India
https://read.qxmd.com/read/38179550/primary-peritoneal-carcinosarcoma-in-a-breast-cancer-patient-harboring-a-germline-brca2-pathogenic-variant-case-report
#9
Luciana Beatriz Mendes Gomes, Renata Lazari Sandoval, Camila Bragança Xavier, Tatiana Strava Correa, Raquel Midori Koga Matuda, Zenaide Silva de Souza, Luiz Guilherme Cernaglia Aureliano de Lima, Mariana Petaccia de Macedo, Filomena Marino Carvalho, Daniele Assad Suzuki
Malignant mixed müllerian tumor (MMMT) is a rare neoplasm, consisting of carcinomatous (epithelial) and sarcomatous (mesenchymal) components that most commonly arise in the endometrium and more infrequently in the ovaries, fallopian tube, cervix, and vagina. Primary peritoneal carcinosarcoma (PPCS) is an extremely rare extragenital presentation of MMMT. Although the occurrence of breast cancer and epithelial ovarian carcinoma in association with BRCA pathogenic variants is firmly established, the etiologic role of these genes in the development of other tumor types is less well known...
2024: Case Reports in Oncology
https://read.qxmd.com/read/38125676/response-of-low-her2-expressing-ovarian-carcinosarcoma-to-trastuzumab-deruxtecan-a-case-report
#10
Peter G Rose
•Treatment options are limited for recurrent ovarian carcinosarcoma (OCS).•A patient with HER2 1 + IHC and negative FISH amplification was treated with trastuzumab deruxtecan.•A durable partial response was achieved, suggesting a possible treatment option for OCS patients with HER2 expression.
December 2023: Gynecologic Oncology Reports
https://read.qxmd.com/read/38100616/top-advances-of-the-year-ovarian-cancer
#11
REVIEW
Melissa A Lumish, Elise C Kohn, William P Tew
Although cure rates remain low and effective screening strategies are elusive, the recent advances in systemic therapies over the past year highlighted in this review have prolonged survival for women with ovarian cancer. In 2022, the first antibody-drug conjugate for platinum-resistant ovarian cancer received accelerated US Food and Drug Administration (FDA) approval. Confirmatory studies examining the efficacy of mirvetuximab and other antibody-drug conjugates are underway. In the upfront setting, the first data establishing an overall survival benefit from poly(ADP-ribose) polymerase inhibitor maintenance was demonstrated after a 7-year follow-up period...
March 15, 2024: Cancer
https://read.qxmd.com/read/38097740/compartment-specific-multiomic-profiling-identifies-src-and-gnas-as-candidate-drivers-of-epithelial-to-mesenchymal-transition-in-ovarian-carcinosarcoma
#12
JOURNAL ARTICLE
C Simon Herrington, Ailsa J Oswald, Lorna J Stillie, Ian Croy, Michael Churchman, Robert L Hollis
BACKGROUND: Ovarian carcinosarcoma (OCS) is an exceptionally aggressive and understudied ovarian cancer type harbouring distinct carcinomatous and sarcomatous compartments. Here, we seek to identify shared and compartment-specific events that may represent potential therapeutic targets and candidate drivers of sarcomatous compartment formation through epithelial-to-mesenchymal transition (EMT). METHODS: We performed multiomic profiling (exome sequencing, RNA-sequencing, microRNA profiling) of paired carcinomatous and sarcomatous components in 12 OCS cases...
December 14, 2023: British Journal of Cancer
https://read.qxmd.com/read/38085958/preferentially-expressed-antigen-in-melanoma-expression-in-uterine-and-ovarian-carcinosarcomas
#13
JOURNAL ARTICLE
Alaaeddin Alrohaibani, Yun Yu, Lina Gao, Kimberly M McLean, Jonathon Hetts, Ozlen Saglam
Carcinosarcoma (CS) is an aggressive form of gynecologic malignancy that accounts for ~5% of carcinomas in the endometrium and ovaries. There has been no significant improvement in survival over the last decades despite additional treatment options. PReferentially Expressed Antigen in MElanoma (PRAME) is an immunotherapy target used for the treatment of several solid tumors. We explored the PRAME protein expression levels in ovarian and uterine CS (n = 29). The expression levels were recorded by H-score (percentage of positively stained cells multiplied by staining intensity) in carcinomatous and sarcomatous components separately and compared by paired t-test...
November 13, 2023: International Journal of Gynecological Pathology
https://read.qxmd.com/read/38085954/ovarian-mesonephric-like-adenocarcinoma-recurring-with-a-rhabdomyosarcoma-component-a-case-report
#14
JOURNAL ARTICLE
Akiko Yamamoto, Takeshi Nagai, Aoi Sukeda, Manami Kajiwara, Masaharu Fukunaga, Toru Sasaki, Yuta Kinoshita, Motoshige Hayashi, Shigehiro Hayashi, Masataka Ono, Masayuki Futagami, Hirotaka Nishi
Mesonephric-like adenocarcinoma (MLA) has recently been described as a tumor of the endometrium or ovaries, which, morphologically and immunohistochemically, resembles mesonephric adenocarcinoma arising mostly in the uterine cervix. Herein, we report, to our knowledge, the first case of ovarian MLA that developed into an extremely rapidly growing recurrent mesonephric-like carcinosarcoma, as confirmed by a genomic profiling test. A 51-year-old woman underwent chemotherapy with complete debulking surgery for ovarian carcinoma...
November 13, 2023: International Journal of Gynecological Pathology
https://read.qxmd.com/read/38072401/incidence-and-treatment-outcomes-of-ovarian-carcinosarcoma-from-the-national-cancer-registry-of-korea
#15
JOURNAL ARTICLE
Hyeong In Ha, Ji Hyun Kim, Jiwon Lim, Yong Jung Song, Young-Joo Won, Myong Cheol Lim
OBJECTIVE: To investigate the incidence and survival outcomes of ovarian carcinosarcoma in Korea between 1999 and 2018. METHODS: Patients diagnosed with ovarian carcinosarcoma between 1999 and 2018 were identified from the Korea Central Cancer Registry (KCCR) and their information was collected. Age-standardized incidence rates (ASRs), annual percent changes (APC), and relative survival rates of ovarian carcinosarcoma were calculated and compared to those of epithelial ovarian cancer...
December 5, 2023: Journal of Gynecologic Oncology
https://read.qxmd.com/read/38029652/molecular-landscape-of-erbb2-her2-gene-amplification-among-patients-with-gynecologic-malignancies-clinical-implications-and-future-directions
#16
JOURNAL ARTICLE
Dimitrios Nasioudis, Stefan Gysler, Nawar Latif, Lory Cory, Robert L Giuntoli, Sarah H Kim, Fiona Simpkins, Lainie Martin, Emily M Ko
OBJECTIVE: Investigate the prevalence of ERBB2/HER2 gene amplification among patients with gynecologic malignancies. METHODS: The American Association of Cancer Research (AACR) Genomics Evidence of Neoplasia Information Exchange (GENIE) (version 13.1) database was accessed and patients with endometrial, ovarian, and cervical cancer were identified. Patients with available data on the presence of copy-number gene alterations were selected for further analysis. Incidence of ERBB2 amplification following stratification by tumor site and histology was evaluated...
November 28, 2023: Gynecologic Oncology
https://read.qxmd.com/read/38015299/rare-non-serous-fallopian-tube-cancers-institutional-experience-and-literature-review
#17
JOURNAL ARTICLE
Dmitrii Sumtsov, Georgyi Sumtsov, Nataliia Hyriavenko, Mykola Lyndin, Kateryna Sikora, Nataliia Kalashnik, Svitlana Smiian, Igor Gladchuk
INTRODUCTION: We reviewed 63 reports from the literature on rare non-serous tumors of the fallopian tubes and carried out a comparative analysis of clinical manifestations and diagnostic methods. We also report our observations from patients with these tumors. MATERIALS AND METHODS: Of 157 patients with primary fallopian tube cancer (FTC) treated in our regional oncological hospital between 1970 and 2020, there were nine (6%) cases of rare non-serous cancers, including one case each of choriocarcinoma, carcinosarcoma, and neuroendocrine tumor, and two cases each of non-keratinizing squamous cell carcinoma, mucinous adenocarcinoma, and clear cell adenocarcinoma...
November 28, 2023: Wiener Medizinische Wochenschrift
https://read.qxmd.com/read/38007705/apobec3c-is-a-novel-target-for-the-immune-treatment-of-lower-grade-gliomas
#18
JOURNAL ARTICLE
Shufa Zhao, Yuntao Li, Jie Xu, Liang Shen
BACKGROUND: Apolipoprotein B mRNA editing catalytic polypeptide-like (APOBEC) type 3C (A3C) has been identified as a cancer molecular biomarker in the past decade. However, the practical role of A3C in lower-grade gliomas (LGGs) in improving the clinical outcome remains unclear. This study aims to discuss the function of A3C in immunotherapy in LGGs. METHODS: The RNA-Sequencing (RNA-seq) and corresponding clinical data were extracted from UCSC Xena and the results were verified in the Chinese Glioma Genome Atlas (CGGA)...
November 26, 2023: Neurological Research
https://read.qxmd.com/read/38001616/new-achievements-from-molecular-biology-and-treatment-options-for-refractory-relapsed-ovarian-cancer-a-systematic-review
#19
REVIEW
Cornelia Bachmann
Ovarian cancer (OC) has a high rate of mortality and is the fifth most common cause of death in females all over the world. The etiology is still unclear. Numerous factors such as smoking, obesity, and unhealthy diet may affect the risk of OC. Having a family history of breast and OC is one of the main risks for developing OC. Mutations of BRCA1/2 are associated with OC risk as well. The histopathological classification of OC reveals the four most common types: serous, clear cell, endometrioid, and mucinous; these are epithelial OC types, and other types are rare...
November 10, 2023: Cancers
https://read.qxmd.com/read/37986208/genomic-and-molecular-characteristics-of-ovarian-carcinosarcoma
#20
REVIEW
Kristy Ramphal, Matthew J Hadfield, Christina M Bandera, Jesse Hart, Don S Dizon
Ovarian carcinosarcoma (OCS) is a rare malignancy with a poor prognosis. It is a biphasic tumor with malignant epithelial and mesenchymal components. A few mutations commonly seen in cancer have been identified in OCS, including TP53, PIK3CA, c-myc, ZNF217, ARID1A, and CTNNB1. Some OCS tumors have shown vascular endothelial growth factor positivity and limited HER2 expression. There is evidence of homologous recombination deficiency in OCS. This malignancy can be categorized as copy number high but has not been shown to have a high tumor mutational burden...
December 1, 2023: American Journal of Clinical Oncology
keyword
keyword
53386
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.